ELI LILLY & Co (LLY) revenue by segment
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3023% above fair value
$1382.75−32.80 (-2.32%)
Close on Nov 18, 2026Market cap $1.30TP/E 44.9Yield 0.45%
Doanh thu theo bộ phận của ELI LILLY & Co
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $65.18B | $45.04B | $34.12B | $28.54B | – | – | – | – | – | – | 100.0% | +44.7% |
| Animal health products | – | – | – | – | – | – | – | – | $3.09B | $3.16B | – | – |
| Human pharmaceutical products | – | – | – | – | – | – | – | – | $19.79B | $18.06B | – | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $60.96B | $40.75B | $28.81B | $25.46B | $25.96B | $22.69B | $20.38B | $19.87B | $18.78B | $20.39B | 93.5% | +49.6% |
| Collaboration and other revenue | $4.22B | $4.30B | $5.31B | $3.08B | $2.36B | $1.85B | $1.94B | $1.63B | $1.20B | $833.70M | 6.5% | -1.7% |
| Jardiance | $3.43B | $3.34B | $2.75B | $2.07B | $1.49B | $1.15B | $944.20M | $658.30M | $447.50M | $201.90M | 5.3% | +2.7% |
| Basaglar | – | $676.90M | $728.30M | $760.40M | $892.50M | $1.12B | $1.11B | $801.20M | $432.10M | $86.10M | – | – |
| Olumiant | – | $957.40M | $922.60M | $830.50M | $1.12B | $638.90M | $426.90M | $202.50M | $45.80M | – | – | – |
| Tyvyt | – | $526.00M | $393.40M | $293.30M | $418.10M | $308.70M | $134.00M | – | – | – | – | – |
| COVID-19 antibodies | – | $0 | $0 | $2.02B | $2.24B | $871.20M | – | – | – | – | – | – |
| Erbitux | – | – | – | – | – | – | – | $635.30M | $645.90M | $687.00M | – | – |
| Trajenta | – | – | $386.90M | $383.70M | $372.50M | $358.50M | $590.60M | $574.70M | $537.90M | $436.60M | – | – |
| Collaboration and other revenue associated with prior period transfers of intellectual property | – | – | $191.60M | $163.40M | $175.00M | $135.60M | $301.50M | $303.20M | $144.90M | $146.10M | – | – |
| Bamlanivimab | – | – | – | – | – | $871.20M | – | – | – | – | – | – |
| Erbitux, Collaboration and Other Revenue | – | – | – | – | – | – | – | $99.20M | $97.70M | $100.00M | – | – |
| Erbitux, Product | – | – | – | – | – | – | – | $536.10M | $548.20M | $587.00M | – | – |
| Effient | – | – | – | – | – | – | – | – | – | $535.20M | – | – |
| Erbitux API | – | – | – | – | – | – | – | – | – | $0 | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $43.48B | $30.38B | $21.79B | $18.19B | $16.81B | $14.23B | $12.72B | $12.39B | $11.41B | $11.51B | 66.7% | +43.1% |
| Outside U.S. | $21.70B | $14.67B | $12.33B | $10.35B | $11.51B | $10.31B | $9.60B | $9.10B | $8.56B | $9.72B | 33.3% | +47.9% |
| Europe | $11.56B | $6.92B | $6.18B | $4.30B | $4.78B | $4.19B | $3.77B | $3.66B | $3.39B | $3.77B | 17.7% | +67.0% |
| Rest of world | $6.06B | $4.27B | $2.95B | $2.85B | – | – | – | – | – | – | 9.3% | +41.8% |
| Japan | $2.13B | $1.82B | $1.67B | $1.75B | $2.37B | $2.58B | $2.55B | $2.41B | $2.34B | $2.33B | 3.3% | +17.5% |
| China | $1.95B | $1.66B | $1.54B | $1.45B | $1.66B | $1.12B | $939.40M | $750.80M | – | – | 3.0% | +17.5% |
| Other foreign countries | – | – | $2.95B | $2.85B | $2.70B | $2.42B | $2.34B | $2.28B | $2.83B | $3.62B | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Eli Lilly (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Eli Lilly, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?